2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.
Despite how common rosacea is, we have a poor understanding of its causes.1-4 Rosacea is a common, chronic skin condition characterized by flushing and blushing that may lead to persistent facial erythema as well as inflammatory papules and...
News | December 19, 2018
The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline...
With the evolution of existing neurotoxins and new agents on the horizon, there may soon be more treatment options than ever. Joel Schlessinger, MD, Founder and Chair of Cosmetic Surgery Forum, discusses the market and announces a change for CSF 2019!
Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Program
The evidence is in: Mental well-being influences the skin.
Helen Taylor, PhD
Understanding rosacea risk factors can allow for earlier, more effective treatment.
Joshua Zeichner, MD
For each individual patient, the patient-physician interaction is unique and requires vulnerability, exposure, and discomfort.
Shannon M. Ruzycki, MD, FRCPC; Danya Traboulsi, MD; and Salima Stanley-Bhanji
Is it time to drop the one-size-fits-all approach and consider remedies of the past?
Kathryn Arnold, BA; and Peter A. Lio, MD
Experts Call for Improved Identification of "High Burden" Rosacea Patients in Everyday Practice
Burt's Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen
IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosacea